China's brain-computer interface (BCI) industry is rapidly transitioning from research to commercialization, driven by four key factors: strong government policy support (including a national roadmap targeting milestones by 2027–2030 and a $165M brain science fund), vast clinical resources with streamlined insurance reimbursement, mature manufacturing infrastructure, and surging state and private investment. Key Chinese startups like NeuroXess, BrainCo, StairMed, and Gestala are advancing both implantable and noninvasive BCI technologies, with the market projected to exceed $530M in 2025 and 120 billion yuan by 2040. Emerging approaches such as ultrasound BCIs are gaining traction for conditions like chronic pain and stroke. China has completed its first fully implanted wireless BCI trial and over 50 flexible implantable BCI clinical trials by mid-2025, positioning Chinese firms to challenge U.S. leaders like Neuralink and Synchron.
Sort: